PresentationI would now like to turn the call over to Holly Manning, Vice President of Investor Relations and External Communications.Good morning, and welcome to Beam Therapeutics Conference Call. [Operator Instructions] Please be advised that this call is being recorded at Beam's request.Holly ManningVice President of Investor Relations & External Communications Thank you, operator. Good morning, everyone, and welcome to Beam's conference call to review top line clinical data from the Phase I/II trial of ...

Financial Data and Key Metrics Changes - ZYNLONTA net product revenues in Q4 2025 were $22.3 million, up from $16.4 million in Q4 2024, with full-year revenues at $73.6 million compared to $69.3 million in 2024 [21][22] - Total operating expenses were $41 million for Q4 2025 and $202.9 million for the full year, with adjusted operating expenses down 15% for Q4 and 6% for the full year compared to the previous year [21][22] - The net loss for Q4 2025 was $6.4 million, significantly reduced from a net loss of $30.7 million in Q4 2024, while the full-year net loss was $142.6 million compared to $157.8 million in 2024 [22][23] Business Line Data and Key Metrics Changes - The company focused on ZYNLONTA, optimizing lifecycle management and advancing clinical trials such as LOTIS-5 and LOTIS-7, which are expected to drive future growth [5][6] - The performance in Q4 was strong, driven by variability in customer ordering patterns and activation of new accounts, indicating a positive trend in sales [8] Market Data and Key Metrics Changes - The company anticipates a peak annual U.S. revenue opportunity for ZYNLONTA of $600 million to $1 billion, contingent on regulatory approval and compendia inclusion [7][11] - The treatment landscape for DLBCL is evolving, with a current 60/40 split between complex therapies and broadly accessible therapies, indicating a competitive market environment [15] Company Strategy and Development Direction - The strategic plan focuses on establishing ZYNLONTA as a backbone therapy in DLBCL, with significant patient benefits expected in indolent lymphomas [6][11] - The company aims to maintain a strong market position despite increased competition from bispecific therapies, leveraging its differentiated clinical profile [5][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving key milestones in 2026, including top-line data for LOTIS-5 and further data for LOTIS-7, which are critical for future growth [25][26] - The company believes it has laid a solid foundation for long-term growth, with a strengthened balance sheet and a cash runway extending into 2028 [10][24] Other Important Information - The company has made significant progress in reducing operating costs by approximately 50% while enhancing its leadership and talent across the organization [5][6] - An amendment to the royalty purchase agreement with HealthCare Royalty has provided greater strategic flexibility for the company [10] Q&A Session Summary Question: How are PFS events tracking for LOTIS-5? - Management is confident in the Q2 timing for the top-line readout and will share primary and secondary endpoints at that time [29][30] Question: Is the $200-$300 million opportunity for LOTIS-5 conservative? - Management believes the profile seen in the safety run-in supports a meaningful role in the second-line DLBCL market, with potential for higher peak sales depending on clinical outcomes [34][35] Question: What is the expected R&D spend moving forward? - R&D expenses are expected to decrease in 2026 and 2027, assuming the current number of trials remains stable [42][44] Question: How should capital allocation priorities be viewed? - The company is focused on driving ZYNLONTA growth and has allocated capital for ongoing trials and pre-launch activities, with strategic flexibility provided by the amended royalty agreement [48][50] Question: What is the current commercial run rate for ZYNLONTA? - The company has maintained its market share despite increased competition, with expectations for significant sales growth following LOTIS-5 approval [58][59]

NovaBridge Biosciences Update Summary Company Overview - **Company**: NovaBridge Biosciences (NasdaqGM:IMAB) - **Focus**: Global biotech platform with a hub-and-spoke business model, primarily in ophthalmology and oncology sectors - **Lead Assets**: - **VIS-101**: A molecule targeting VEGF-A and ANG-2, designed for retinal vascular diseases - **Givastomig**: A bispecific antibody for gastric cancer, targeting Claudin 18.2 and 4-1BB - **Financial Position**: As of the last SEC filing, the company has $228 million in cash, providing operational runway through 2028 [5][6] Industry Context - **Market Need**: Over 57 million people globally are affected by retinal vascular diseases, including wet AMD, diabetic macular edema, and retinal vein occlusion, indicating a significant unmet need for effective therapies [16][17] - **Competitive Landscape**: Current treatments like Lucentis and Eylea have shorter treatment intervals, while VIS-101 aims for longer intervals (Q8 to Q24 weeks) [18][19] Clinical Development - **VIS-101 Phase IIa Trial**: - **Design**: Multicenter, open-label, randomized study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with neovascular AMD [25][26] - **Patient Population**: 38 patients randomized in a 2-to-1 ratio to receive either 6 mg or 3 mg of VIS-101 [26] - **Results**: - Rapid and robust BCVA gain observed, with approximately 70% of treatment-naive patients being treatment-free at 4 months and about 40% at 6 months [31][32] - Central subfield thickness (CST) decreased by over 100 microns after the first injection [31] - Safety profile: Well-tolerated with no dose-limiting toxicities reported [34] Key Findings - **Durability**: VIS-101 demonstrated a potential best-in-class durability with treatment-free intervals extending up to 24 weeks [40] - **Comparison with Competitors**: VIS-101 shows double the anti-VEGF inhibition and 17 times the anti-ANG-2 inhibition compared to faricimab [35] - **Management Team**: Led by experienced professionals, including Dr. Emmett Cunningham, who has a strong background in ophthalmology and drug development [11][12] Future Plans - **Next Steps**: - Initiation of Phase IIb study in China in the second half of 2026 - Global Phase III program expected to begin in 2027 [40][41] - **Partnership Strategy**: Open to discussions for partnerships but currently does not require one for global development [70] Additional Insights - **Clinical Trial Design**: The trial's retreatment criteria were designed to prioritize patient safety, requiring either a decrease in vision or an increase in anatomical parameters for retreatment [53] - **Regulatory Considerations**: Future trials will likely focus on treatment-naive patients, as regulatory agencies prefer this population for clearer efficacy assessments [79] This summary encapsulates the key points from the NovaBridge Biosciences update, highlighting the company's strategic focus, clinical advancements, and future directions in the biotech landscape.

Core Viewpoint - Kyverna Therapeutics is discussing top line data from the KYSA-8 registrational trial of mivocabtagene autoleucel (miv-cel) for patients with stiff person syndrome (SPS) [2] Group 1 - The conference call includes remarks from key executives such as the CEO and Chief Medical and Development Officer [4] - Investors are encouraged to visit the Investor Relations section of the company's website for press releases and presentation materials [3]

Summary of Innovent (1801.HK) Conference Call Company Overview - **Company**: Innovent Biologics, Inc. (1801.HK) - **Date**: 23 May 2025 - **Market Cap**: HK$92,786 million (approximately US$11,855 million) [2][9] Key Industry Insights - **Product Focus**: IBI363, an investigational drug for various cancers including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and melanoma. - **Clinical Data**: - In IO-treated squamous NSCLC, IBI363 demonstrated an overall response rate (ORR) of 43.3% (13/30) and a median progression-free survival (mPFS) of 7.3 months, suggesting potential superiority over docetaxel (mPFS ~4 months, mOS 10-12 months) [2][4]. - In third-line or later MSS/pMMR CRC, IBI363 showed an ORR of 23.5% (16/68) when combined with Bevacizumab (Beva) [2][4]. - **Regulatory Actions**: Innovent has initiated a registrational trial for IBI363 in IO-naïve melanoma and is in discussions with regulatory agencies regarding potential registrational trials in IO-treated squamous NSCLC and CRC [2][4]. Financial Projections - **Target Price**: HK$60.00, indicating an expected share price return of 6.7% [2][9]. - **Valuation Method**: Discounted Cash Flow (DCF) approach, with a terminal growth rate of 4% and a weighted average cost of capital (WACC) of 10.3% [9]. Risk Factors - **High Risk Rating**: The stock is classified as high risk due to: 1. Historical lack of profitability and forecasted periods without profit. 2. Potential sales underperformance relative to expectations. 3. Intense competition for IBI362 in obesity treatment. 4. Risks associated with research and development failures. 5. Regulatory risks that could hinder stock performance [10][2]. Additional Considerations - **Investment Rating**: The stock is rated as "Buy" with a high-risk designation, reflecting the volatility and fundamental criteria associated with the company [21][22]. - **Expected Dividend Yield**: 0.0%, indicating no dividends are anticipated in the near term [2][9]. This summary encapsulates the critical insights from the Innovent conference call, highlighting the company's clinical advancements, financial outlook, and associated risks.